Next Article in Journal
Effect of Nitric Acid Modification on Characteristics and Adsorption Properties of Lignite
Previous Article in Journal
Development of Environmental Friendly Dust Suppressant Based on the Modification of Soybean Protein Isolate
Previous Article in Special Issue
Accelerating Biologics Manufacturing by Modeling or: Is Approval under the QbD and PAT Approaches Demanded by Authorities Acceptable without a Digital-Twin?
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessFeature PaperArticle
Processes 2019, 7(3), 166; https://doi.org/10.3390/pr7030166

Accelerating Biologics Manufacturing by Upstream Process Modelling

Institute for Separation and Process Technology, Clausthal University of Technology, Leibnizstr. 15, 38678 Clausthal-Zellerfeld, Germany
*
Author to whom correspondence should be addressed.
Received: 2 February 2019 / Revised: 16 March 2019 / Accepted: 18 March 2019 / Published: 21 March 2019
(This article belongs to the Special Issue Processes Accelerating Biologics Manufacturing by Modelling)
  |  
PDF [4248 KB, uploaded 21 March 2019]
  |  

Abstract

Intensified and accelerated development processes are being demanded by the market, as innovative biopharmaceuticals such as virus-like particles, exosomes, cell and gene therapy, as well as recombinant proteins and peptides will possess no available platform approach. Therefore, methods that are able to accelerate this development are preferred. Especially, physicochemical rigorous process models, based on all relevant effects of fluid dynamics, phase equilibrium, and mass transfer, can be predictive, if the model is verified and distinctly quantitatively validated. In this approach, a macroscopic kinetic model based on Monod kinetics for mammalian cell cultivation is developed and verified according to a general valid model validation workflow. The macroscopic model is verified and validated on the basis of four decision criteria (plausibility, sensitivity, accuracy and precision as well as equality). The process model workflow is subjected to a case study, comprising a Chinese hamster ovary fed-batch cultivation for the production of a monoclonal antibody. By performing the workflow, it was found that, based on design of experiments and Monte Carlo simulation, the maximum growth rate µmax exhibited the greatest influence on model variables such as viable cell concentration XV and product concentration. In addition, partial least squares regressions statistically evaluate the correlations between a higher µmax and a higher cell and product concentration, as well as a higher substrate consumption. View Full-Text
Keywords: biologics; manufacturing; process intensification; modelling; upstream processing; Monod kinetics biologics; manufacturing; process intensification; modelling; upstream processing; Monod kinetics
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kornecki, M.; Strube, J. Accelerating Biologics Manufacturing by Upstream Process Modelling. Processes 2019, 7, 166.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Processes EISSN 2227-9717 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top